Testosterone deficiency and cardiovascular mortality by Morgentaler, Abraham
 
Testosterone deficiency and cardiovascular mortality
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Morgentaler, Abraham. 2015. “Testosterone deficiency and
cardiovascular mortality.” Asian Journal of Andrology 17 (1):
26-31. doi:10.4103/1008-682X.143248.
http://dx.doi.org/10.4103/1008-682X.143248.
Published Version doi:10.4103/1008-682X.143248
Accessed February 17, 2015 11:22:49 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890699
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAAsian Journal of Andrology (2015) 17, 26–31   
© 2015 AJA, SIMM & SJTU. All rights reserved 1008-682X
www.asiaandro.com; www.ajandrology.com
men. The majority of those studies have shown a significant association 
between lower serum T concentrations and mortality, with a smaller 
number showing no association. None of these observational studies 
has shown increased mortality of normal serum T compared with low 
serum T concentrations. However, two recent retrospective studies 
reported increased adverse CV events, including mortality, in men 
who received T prescriptions compared with men who did not.6,7 
Those studies have created a firestorm of media attention as well 
as scrutiny from regulatory bodies regarding the issue of T and CV 
risk. Despite serious methodological and data management concerns 
regarding those two studies (see below), their impact on the medical 
“conversation” regarding T and CV issues has been enormous. It is thus 
particularly timely, then, to review the literature on this topic so as to 
provide context and perspective on this important issue.
A number of excellent systematic reviews and meta-analyses of 
mortality and other CV adverse effects with TTh have been published 
over the last several years.2,8–10 The purpose of this article is not to 
repeat those analyses, but rather to review the literature, highlighting 
notable results and providing an overview of those analyses. Most of 
these studies investigated overall mortality, whereas others provided 
specific information on CV mortality. However, it should be noted 
that overall mortality is often used as a nonspecific surrogate for 
CV risk since CV disease is the greatest single cause of mortality in 
industrialized countries.11
TESTOSTERONE AND CARDIOVASCULAR MORTALITY
The association of serum T and CV mortality has been extensively 
studied (Table 1).
INTRODUCTION
As the use of testosterone (T) therapy (TTh) has increased substantially 
over the last decade,1 there has been increased attention paid to the 
health consequences of testosterone deficiency (TD), as well as to 
the potential risks of its treatment. One of the key topics in this area 
is the relationship of TD to cardiovascular (CV) health, particularly 
CV mortality. The purpose of this article is to review the literature 
regarding this issue.
In the 1970s and 1980s, as epidemiologic studies demonstrated 
that men suffered from higher rates of myocardial infarctions (MIs) 
and CV deaths than women for every decade of life, it was speculated 
that T played a significant role in CV disease, as a clear difference 
between men and women was the presence of substantial serum 
concentrations of T in men.2 However, this belief largely disappeared 
once studies investigating the relationship of T and CV disease began 
to show that atherosclerosis in men was more prevalent in men with 
low T concentrations, and men with higher T concentrations appeared 
to be protected.3
Over the last 20 years, the major focus of potential risks of TTh has 
been its impact on prostate cancer (PCa). Whereas it had been long 
assumed that raising serum T would increase the risk of PCa and would 
cause any existing foci of PCa to grow rapidly,4 data accumulated over 
nearly 20 years failed to support this belief.5 Curiously, just as concerns 
regarding PCa have declined, we are once again faced with concerns 
regarding CV risk.
As reviewed in greater detail below, a sizable number of 
observational studies have investigated the association of serum T 
concentrations and mortality, and more specifically, CV mortality, in 
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New concerns have been raised regarding cardiovascular (CV) risks with testosterone (T) therapy (TTh). These concerns are based 
primarily on two widely reported retrospective studies. However, methodological flaws and data errors invalidate both studies as 
credible evidence of risk. One showed reduced adverse events by half in T‑treated men but reversed this result using an unproven 
statistical approach. The authors subsequently acknowledged serious data errors including nearly 10% contamination of the 
dataset by women. The second study mistakenly used the rate of T prescriptions written by healthcare providers to men with recent 
myocardial infarction (MI) as a proxy for the naturally occurring rate of MI. Numerous studies suggest T is beneficial, including 
decreased mortality in association with TTh, reduced MI rate with TTh in men with the greatest MI risk prognosis, and reduced CV 
and overall mortality with higher serum levels of endogenous T. Randomized controlled trials have demonstrated benefits of TTh 
in men with coronary artery disease and congestive heart failure. Improvement in CV risk factors such as fat mass and glycemic 
control have been repeatedly demonstrated in T‑deficient men treated with T. The current evidence does not support the belief that 
TTh is associated with increased CV risk or CV mortality. On the contrary, a wealth of evidence accumulated over several decades 
suggests that low serum T levels are associated with increased risk and that higher endogenous T, as well as TTh itself, appear to 
be beneficial for CV mortality and risk.
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Several studies of community-dwelling men have been performed to 
investigate the relationship of endogenous serum T to CV mortality. One 
of these was the European Prospective Investigation into Cancer in Norfolk 
by Khaw et al.12 This was a nested case-control study based on 11 606 men 
aged 40–79 years, surveyed in 1993–1997, and followed-up to 2003. The 
study examined the prospective relationship between endogenous serum 
T concentrations and mortality due to all causes, CV disease, as well as 
cancer. The study population was comprised of 825 men without cancer 
or known CV disease at baseline who subsequently died, and these results 
were compared with a control group of 1489 men who were still alive, 
matched for age and date of baseline visit.12
The primary result was that overall mortality and CV mortality 
were inversely associated with serum T concentrations.12 Analysis 
by quartiles for serum T showed that men in the lowest quartile 
were at greatest risk for CV and overall mortality, whereas men with 
in the upper quartiles were at reduced risk of death. Odds ratios 
(with 95% confidence interval [CI]) for mortality for increasing 
quartiles of endogenous T compared with the lowest quartile were 
0.75 (0.55–1.00), 0.62 (0.45–0.84), and 0.59 (0.42–0.85). The statistical 
significance associated with all of these was P < 0.001. These last results 
were based on the adjustment for multiple variables, including age, 
body mass index (BMI), blood pressure (BP), smoking history, and 
diabetes.12
Another study by Haring et al. investigated overall mortality as 
well as CV mortality using data from the prospective population-based 
Study of Health in Pomerania.13 Among 1954 men with serum T 
concentrations at baseline, there were 195 deaths, with a mean follow-up 
period of 7.2 years. The authors reported that men with low serum T, 
defined as < 8.7 nmol l−1 (250 ng dl−1), demonstrated significantly greater 
all-cause mortality than men with higher serum T (hazard ratio [HR]: 
2.24; 95% CI: 1.41–3.57), as well as greater CV mortality (HR: 2.56; 95% 
CI: 1.15–6.52). Increased risk of low T for mortality was seen in 
younger (20–59 years) and older (60–79 years) age groups, with the 
greatest risk noted in the older population.13
Table 1: Association between levels of endogenous testosterone and mortality
Study Sub‑fraction 
of testosterone 
used for analysis
Sample size Age range/mean 
age (year)
Mean 
follow‑up 
period (year)
Major finding Remarks
Haring et al. 201013
CS
SHIP
TT 1954 20–79/58.7 7.2 Low TT is associated with 
increased risk of mortality 
from all causes and CV 
disease
HR of low TT for all-cause mortality: 
1.92; 95% CI: 1.18–3.14; P<0.001
HR of low TT for CV mortality: 2.56; 
95% CI: 1.15–6.52; P<0.05
Malkin et al. 201060
FU
TT
BT
930 Not reported 6.9 Low BT is inversely 
associated with time to 
all-cause and vascular 
mortality
HR of low BT for all-cause mortality: 
2.2; 95% CI: 1.4–3.6; P<0.0001
HR of low BT for vascular mortality: 
2.2; 95% CI: 1.2–3.9; P=0.007
Menke et al. 201061
CS
NHANES III
TT
BT
FT
1114 ≥20/40 16 Decrease in FT and BT from 
90th to 10th percentile is 
associated with increased 
risk of all-cause and CV 
mortality during the first
9 years of follow-up
HR of FT decrease for all-cause 
mortality: 1.43; 95% CI - 1.09–1.87
HR of BT decrease for all-cause 
mortality: 1.52; 95% CI: 1.15–2.02
HR of FT decrease for CV mortality: 
1.53; 95% CI: 1.05–2.23
HR of BT decrease for CV mortality: 
1.63; 95% CI: 1.12–2.37
Vikan et al. 200962
CS
Tromsø
TT
FT
1568 Not 
reported/59.6
11.2 24% higher risk of all-cause 
mortality for men with low 
FT levels
HR of low FT for all-cause mortality: 
1.24; 95% CI: 1.01–1.54
Tivesten et al. 200963
CS
MrOs
TT
FT
2639 with TT; 
2618 with FT
69–80/75.4 4.5 Increasing levels of TT and 
FT are associated with 
decreasing risk of all-cause 
mortality
HR of high TT for all-cause mortality: 
0.59; P<0.001
HR of high FT for all-cause mortality: 
0.50; P<0.001
Laughlin et al. 200864
CS
Rancho Bernardo study
TT
FT
794 63–78.9/71.2 11.8 Low TT and BT are associated 
with higher risk of all-cause 
and CV mortality
HR of low TT for all-cause mortality: 
1.44; P<0.002
HR of low BT for all-cause mortality: 
1.50; P<0.001
HR of low TT for CV mortality: 1.38; 
95% CI: 1.02–1.85
HR of low BT for CV mortality: 1.36; 
95% CI: 1.04–1.79
Khaw et al. 200712
CCS
EPIC-Norfolk
TT 11,606 40–79/67.3 7 Low TT is associated with 
higher risk of all-cause and 
CV mortality. Same trend 
was noted for CHD mortality 
but statistical significance 
was not achieved
OR of low TT for all-cause mortality: 
0.59; P<0.001
OR of low TT for CV mortality: 0.53; 
P<0.01
Araujo et al. 200714
FU
MMAS
TT
FT
1686 40–80 15.3 High FT and low DHT 
levels are associated with 
ischemic heart disease
TT and SHBG levels are not associated 
with all-cause mortality
Shores et al. 200665
CS
Veterans
TT 858 ≥40/61.4 4.3 Low TT is associated with 
higher risk of all-cause 
mortality
HR of low TT for all-cause mortality: 
1.88; P<0.001
BT: bioavailable testosterone; CAD: coronary artery disease; CCS: case-control study; CHD: coronary heart disease; CI: confidence interval; CS: cohort study; CV: cardiovascular; 
FAI: free androgen index; FT: free testosterone; FU: follow-up study; HR: hazard ratio; OR: odds ratio; TT: total testosterone; DHT: dihydrotestosterone; SHBG: sex hormone binding 
globulin; SHIP: study of health in pomeranial; NHANES: National Health and Nutrition Examination Survey; MrOs: Osteoporotic Fractures in Men Study; EPIC-Norfolk: European 
Prospective Investigation into Cancer in Norfolk; MMAS: Massachusetts Male Aging StudyAsian Journal of Andrology 
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Not all population-based studies have demonstrated increased 
overall or CV mortality with lower serum T concentrations. Araujo 
et al. analyzed results for 1709 men in the Massachusetts Male Aging 
Study with ages ranging from 40 to 79 years.14 There were 395 deaths 
during 15.3 years of follow-up. No significant association was noted 
with serum T concentrations for overall or CV mortality.
Separately, Araujo et al.15 performed a meta-analysis of serum T 
concentrations and mortality, both overall and specific to CV 
disease. They selected 12 studies of serum T concentrations in 
community-dwelling men, 11 of which were eligible for all-cause 
mortality assessment, involving 16 184 subjects, and 7 of which 
were eligible for CV mortality assessment, involving 11 831 subjects. 
A clear, significant association was noted for increased overall 
mortality, with a relative risk of 1.35 (95%CI: 1.13–1.62), and 
strongly suggestive but nonsignificant relative risk for CV mortality 
of 1.25 (95%CI: 0.97–1.60).15
Corona et al.16 performed a meta-analysis of a broader literature set 
of 70 studies, including men with co-morbidities and clinic populations, 
consisting of 54 cross-sectional studies, 10 longitudinal studies, and 
6 randomized, controlled intervention studies. In cross-sectional 
studies, lower T levels were significantly associated with the presence 
of any CV disease using a logistic regression model with adjustment for 
age and BMI (HR = 0.837; 95%CI: 0.823–0.852), and also when diabetes 
and hypertension were added as covariates (HR = 0.536; 95%CI: 
0.447–0.606). Longitudinal studies involving 12 375 men revealed lower 
T levels in men with overall and CV mortality. The six randomized 
controlled trials were performed in men with documented coronary 
artery disease, with the primary endpoint of time to development of 
1 mm ST depression on electrocardiogram (EKG) during exercise. 
Men treated with T compared with men who received placebo were 
able to exercise longer before demonstration of coronary ischemia as 
represented by ST segment depression.16
TESTOSTERONE PRESCRIPTIONS AND CARDIOVASCULAR 
EVENTS AND MORTALITY
Against a longstanding backdrop of more than 30 years of studies 
suggesting that low levels of T represent an increased risk for CV and 
overall mortality,15 and evidence that lower serum T concentrations 
also are associated with CV disease, including incident coronary artery 
disease17–19 and atherosclerosis,3,20 two recent studies have gained 
considerable media and scientific attention for reporting increased 
CV events and/or mortality in men who received a T prescription.
The first of these was published in November 2013 by Vigen et al.7 
This was a retrospective analysis of a database accumulated from the 
Veterans Administration healthcare system of 8709 men who had 
undergone coronary angiography and had a documented serum T 
concentration < 300 ng dl−1. The authors looked at rates of MI, stroke, 
and death in men who eventually received a prescription for TTh 
and compared those adverse event rates to men who were untreated. 
Although no statistically significant differences were noted at years 
1, 2, or 3, the overall rate of events over the course of the study was 
reported to be significantly higher in T-treated men by 29%. The 
authors concluded that TTh was associated with an increased risk of 
MI, stroke and death.7
However, it soon came to light that the actual rate of adverse events was 
only half as great in the T group (123 events in 1223 men at risk = 10.1%) 
as in the untreated group (1587 events in 7486 men = 21.2%).21 The 
authors never acknowledged this fact, and came to their opposite 
interpretation of the data based on complex statistics that included 
adjustment for more than 50 variables. The methodology in this study, 
that is, stabilized inverse propensity treatment weighting (IPTW) 
applied to Kaplan–Meier curves with time as a covariate, had only been 
described 1-year earlier in a separate article by senior author Michael Ho 
in which the novelty and lack of documented accuracy was underscored 
by the following statement: “clearly, assessing and confirming adequate 
covariate balance in IPTW time-varying models is challenging and 
needs further study. Further work with simulations and contrasts to 
other methods and other study applications would help elucidate the 
advantages and disadvantages of this approach.”22
The study by Vigen et al.7 has already undergone two published 
corrections,23,24 the most recent for a series of data errors in which the 
numbers of men in one group was decreased by > 1000 individuals, 
the numbers in a second group were increased by > 900 individuals, 
and nearly 10% of the all-male dataset was found to be contaminated 
by women.24 Due to these errors, 29 medical societies have called for 
retraction of the article, asserting “gross data mismanagement and 
contamination,” that rendered the study “no longer credible.”25
The second study, published in January 2014 by Finkle et al. 
was an analysis of health insurance claims data that reported a 36% 
increased rate of nonfatal MI in the 90d following receipt of a T 
prescription compared with the 12 prior months.6 Comparison with 
men who received a prescription for a phosphodiesterase type 5 
inhibitor (PDE5i) revealed no increased rate of MI following the 
prescription. The authors’ concluded that T prescriptions were 
associated with an increased risk of nonfatal MI.
The strength of the study was the very large population size of 
55 593 men. However, important weaknesses render the results highly 
questionable. Methodologically, the comparison of postprescription MI 
rates to MI rates prior to the prescription are meaningless, since this was 
not an experiment with a run-in period, but rather a retrospective look 
at what actually happened in clinical practice. The post prescription 
MI rate, with some caveats, may provide a reasonable estimate of 
what actually occurred in this population. However, since these men 
were included only because they had already been prescribed T, the 
preprescription MI rate reflects only how often healthcare providers 
were willing to write a prescription for men with a history of MI within 
the prior 12 months. Any reluctance to prescribe this medication would 
result in low value, and the ratio of post- to pre-prescription MI rates 
will falsely appear to be increased.
In addition, there was no information available regarding any 
standard CV risk factors, such as BP, smoking history, or obesity, and 
no information for any blood test result, such as serum T, or lipid 
profiles. Moreover, the reported rates of MI before the T prescription 
(3.48 per 1000 person-years) and after (4.75 per 1000 person-years) 
were both substantially lower than would be predicted based on the 
NIH risk calculator for similar-aged US men using favorable parameters 
(13 per 1000 person-year), specifically age 54 years (same as mean 
age of study participants), nonsmoker, total cholesterol 230 mg dl−1, 
high-density lipoprotein 40 mg dl−1, systolic BP 140 mm Hg−1.26 
Finally, the comparison with men who received a PDE5i prescription 
was inappropriate. These were two dissimilar groups treated with 
dissimilar medications for dissimilar indications. This is a classic case 
of apples and oranges that provides no useful information. Despite 
the considerable attention given to this article, this dataset provides 
no credible data indicating that TTh is associated with increased risk 
of MI.21
It is important to note that two prior studies have examined the 
effect of T prescriptions on mortality in men with TD.27,28 The first, 
by Shores et al.28 investigated 1031 men in the VA healthcare system 
with documented serum T < 250 ng dl−1. The mean age was 62 years, Asian Journal of Andrology 
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and mean follow-up was 40.5 months. Mortality in T-treated men 
was reduced by approximately half in treated men compared with 
untreated men, at 10.3% versus 20.7%, respectively (P = 0.0001). 
The mortality rate for men who received TTh was 3.4 deaths per 100 
person-years, and 5.7 deaths per 100 person-years in untreated men. 
Multivariate adjustment for age, BMI, T level, medical morbidity, 
diabetes, and coronary heart disease yielded a HR of 0.61 (95%CI: 
0.42–0.88; P = 0.008), indicating a significant reduction in mortality 
with TTh.28
A second study demonstrating reduced mortality with TTh 
was performed by Muraleedharan et al. in a group of 581 diabetic 
men followed for a mean of 5.8 years.27 Men with low T, defined 
as serum T < 10.4 nmol l−1 (300 ng dl−1), demonstrated increased 
mortality compared with men with T values above this threshold. 
Adjusted mortality in the low T group was 17.2% compared with 
9% in the normal T group (P = 0.003). In these populations, the 
multivariate-adjusted HR for decreased survival was 2.02 (P = 0.009, 
95%CI: 1.2–3.4). Among men who received TTh, mortality was 
reduced to 8.4% compared with 19.2% in the men with low T who 
were untreated. The HR for decreased survival in the untreated group 
was 2.3 after multivariate adjustment (95% CI: 1.3–3.9, P = 0.004).27
Although these two studies provide reassuring and suggestively 
beneficial results for CV effects and mortality related to T prescriptions, 
neither gained the media attention of the articles alleging increased 
risks. Ironically, the validity of these results is supported by the absolute 
event rates in the study by Vigen et al. in that study as well as those by 
Shores et al.28 and Muraleedharan et al.27 the event rate were lower by 
approximately half in T-deficient men who received a T prescription 
compared with untreated men.
OTHER REPORTS OF INCREASED CARDIOVASCULAR RISK 
WITH TESTOSTERONE THERAPY
In addition to the articles by Vigen et al.7 and Finkle et al.6 reporting 
increased CV risk with T prescriptions, there appear to be only two 
additional studies in the literature that reported increased CV risks with 
TTh. The first, conducted by Basaria et al. was a prospective randomized 
trial designed to investigate whether T gel provided greater muscular 
and functional benefits over placebo in an elderly, frail population 
of men.29 The study was terminated early due to the observation of 
increased adverse events categorized as “CV” in the T arm. There were 
23 of these events in the T arm and 5 in the placebo arm.
It is important to note that this study was not designed to investigate 
CV events, and none of the reported events were primary or secondary 
endpoints. A large majority of reported “events” were anecdotal and 
of questionable clinical importance, including palpitations, pedal 
edema, and premature ventricular contractions noted on EKG. None 
of these items was defined prior to study enrollment, and no attempt 
was made to assess these in both groups. Although there were 5 major 
adverse cardiac events (1 death, 2 MI’s, one coronary revascularization, 
one stroke), all in the T group, one must be extremely cautious in 
drawing conclusions from rare events. In a similar study in frail elderly 
men performed in the UK by Srinivas-Shankar et al.30 there were two 
major CV events (1 death, 1 MI), both occurring in the placebo group. 
As the authors Basaria et al.29 themselves stated “the lack of a consistent 
pattern in these events and the small number of overall events suggest 
the possibility that the differences detected between the two trial groups 
may have been due to chance alone.”
In the absence of predefined endpoints or any attempt to 
systematically investigate both groups for these adverse events, this 
study provides no meaningful information regarding CV risks.
The second article frequently cited as support for increased 
CV risks with T administration is the meta-analysis by Xu et al.31 
The authors assessed CV events in 27 placebo-controlled T 
studies of 12 weeks duration or longer, and reported that CV events 
were greater in men who received T compared with placebo. Just two 
of the 27 studies contributed 35% of all CV events in the T arm. One 
is a study by Basaria et al.29 discussed above, in which 18 of 23 events 
(incorrectly reported as 25 events by Xu et al.31) would not normally be 
included in reporting of CV events. The other is a 1986 Copenhagen 
study in which a nonapproved oral formulation of micronized T was 
administered at a remarkably high dose of 600 mg daily to men with 
cirrhosis of the liver, resulting in serum T concentrations exceeding 
4000 ng dl−1 (approximately 140 nmol l−1) in a quarter of the T group, 
and with levels reaching as high as 21 000 ng dl−1 (745 nmol l−1), a value 
approximately 20 times the upper limit of the normal range. Since oral 
T is known to cause liver toxicity via a first-pass effect, it should be 
no surprise that markedly supraphysiologic T doses in a hepatically 
compromised population would prove harmful. This study provides 
no clinically relevant information, and inclusion of its results in the 
meta-analysis is misleading.
Without the contributions of the Copenhagen study and the 
nonmajor CV events in the study by Basaria et al.29 the rates of adverse 
CV events in the T and placebo groups are similar, with a slightly 
lower rate in the T group (78 events in 1599 men, 4.88% vs 60 events 
in 1174 men, 5.1%, respectively). It should be underscored that several 
other meta-analyses have also been published, with none indicating 
increased CV risk with T administration versus placebo.8–10,32
Reassuringly, the latest study to investigate this issue revealed no 
increased MI risk among men who received TTh. On the contrary, in this 
study of 25 420 US Medicare recipients 65 years and older, a significant 
trend towards reduced MI rates were noted with increasing quartiles of 
risk.33 For men in the highest prognostic MI risk quartile, treatment with 
TTh was associated with reduced risk (HR = 0.69; 95% CI = 0.53–0.92).
DISCUSSION
The issue of CV safety with TTh has suddenly become a major 
healthcare issue. Although TTh has been controversial for many 
years, the rapid increase in prescriptions over the last decade and 
direct-to-consumer marketing in the US has led to a parallel increase in 
scrutiny for adverse effects. The issue is confounded by opinion pieces 
in medical and lay publications criticizing pharmaceutical company 
for profits for what some have asserted is not a real medical condition. 
A tripling in T prescriptions in the US over the last decade has been 
cited as ipso facto evidence that TTh is overused and abused.33 With 
this as a background, two retrospective studies of questionable merit 
have been widely hailed as evidence that TTh is risky, contradicting a 
wealth of data accumulated over several decades.
Any objective review must consider the evidence as it exists, based 
on the quality of the methodology and results, rather than what has 
been asserted about those studies, including interpretations by the 
authors. Although all new information merits consideration, this 
does not mean that results from every new study must be accepted 
as credible, particularly if they contradict prior existing information. 
This is the situation in which we find ourselves with publication of the 
two studies, by Vigen et al.7 and by Finkle et al.6 that reported increased 
CV risks with TTh in contrast to a wealth of prior literature that strongly 
pointed in the opposite direction. When surprising or contrary results 
are obtained, the explanation is often found in the methodology.
This is the case here. The absolute rate of events in the study by 
Vigen et al.7 demonstrated a reduced risk of stroke, MI, and death Asian Journal of Andrology 
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in men who received a T prescription compared with men who did 
not. The authors reported opposite results using a new statistical 
methodology-stabilized inverse propensity weighting applied to 
Kaplan–Meier curves-that is still in development without adequate 
confirmation by large published studies. As the authors explained, this 
methodology in this study resulted in an adverse event in the T group 
being counted as greater than one event, whereas a similar event in 
the untreated group was counted as less than one event.34 Specifically, 
one death, MI, or stroke in the T group counted as approximately 
3 events,35 whereas the same event in the untreated group counted as 
approximately 0.9 events. This is clearly a troubling statistical approach.
Moreover, the series of data errors acknowledged by the authors, 
including errors of > 1000 men in one category, >900 in another, and 
contamination by nearly 10% women in one part of the dataset indicates 
serious problems with data management. In response to these errors, 
29 medical societies from around the world have called for retraction 
of this article, citing “gross data mismanagement and contamination,” 
rendering the study “no longer credible.”25
The article by Finkle et al.6 actually revealed low rates of MI in 
men treated with T. The report of an increased risk following receipt 
of a prescription was only in comparison to an artificially reduced 
prescribing rate of T to men with prior history of MI within the last 
12 months.
In contrast, two prior studies have shown that mortality is reduced, 
by approximately half, in men who received a T prescription compared 
with those who did not,27,28 findings consistent with the actual rates 
reported by Vigen et al.7 In addition, a majority of observational studies 
have found that low endogenous serum T levels are associated with 
increased mortality. Although a few studies showed no association with 
serum T concentrations, it must also be noted that none have shown 
that normal serum T concentrations are associated with increased risk.
Is it possible that the recent worrisome studies uncovered a 
population at risk? This also appears not to be the case. English et al. 
performed a T versus placebo-controlled trial of exercise in men with 
known coronary artery disease, and investigated time to 1 mm ST 
depression by EKG as an indication of ischemia.36 Men who received 
TTh were able to exercise significantly longer without ischemia 
compared with men who received placebo. In men with congestive heart 
failure, those who received T demonstrated greater walking distance and 
other functional endpoints compared with those who received placebo.38
It should also be noted that TTh has been shown uniformly and 
repeatedly to improve several known CV risk factors, including reduced 
fat mass, body fat percent, and waist circumference, and increased 
lean mass.37–48 Numerous studies have also shown improved glycemic 
control39–42,47–51 and reductions in insulin resistance.38,39,48,49,51–59 Taken 
as a whole, then, the evidence strongly points to improved CV status 
with normal serum T or treatment with TTh in men with TD, and most 
observational studies regarding T and mortality appear to support 
this concept.
CONCLUSIONS
A long history of studies investigating T and CV risks, specifically 
mortality, reveals important associations with low T and mortality 
with higher serum T appearing to be protective in a majority of studies. 
Several retrospective observational studies have now shown reduced 
mortality and CV adverse events in men who received T compared with 
untreated men. Although no definitive, large, prospective studies have 
yet been performed, a substantial literature accumulated over several 
decades fails to provide any credible evidence that TTh is associated 
with increased CV mortality or major adverse CV events.
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